Expert Highlights Potential Utility of Amivantamab in Advanced EGFR+ NSCLC


Byoung Chul Cho, MD, PhD, highlights ongoing trials assessing intravenous and subcutaneous amivantamab in EGFR-mutant non–small cell lung cancer.

In a conversation with CancerNetwork® at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Byoung Chul Cho, MD, PhD, discussed the potential activity of amivantamab-vmjw (Rybrevant) in combination with lazertinib (Leclaza) for those with advanced non–small cell lung cancer (NSCLC) harboring EGFR mutations based on results from the phase 1/1b CHRYSALIS-2 trial (NCT04077463).

Cho, a medical oncologist and professor in the Division of Medical Oncology at Yonsei Cancer Center, Yonsei University College of Medicine in Seoul, South Korea, stated that this combination therapy demonstrated utility across multiple EGFR mutation subtypes, including EGFR exon 20 insertion mutations. Additionally, findings from an abstract published ahead of the meeting highlighted enduring antitumor activity in patients with previously untreated disease as well as those with progression on afatinib (Gilotrif).1 Safety findings indicated that most adverse effects were generally grade 1/2 toxicities related to EGFR and MET mutations.

Cho will present detailed results from the CHRYSALIS-2 trial in a rapid oral abstract session during the meeting.

Beyond the CHRYSALIS-2 trial, Cho detailed other ongoing studies assessing treatment with amivantamab in different EGFR-mutant NSCLC populations. For example, the investigators of the phase 2 PALOMA-2 trial (NCT05498428) are evaluating the activity and safety of subcutaneous amivantamab for various cohorts of patients with EGFR-mutated NSCLC.2 In this trial, amivantamab will be administered subcutaneously in combination with different agents, which include lazertinib, carboplatin, and pemetrexed.


Based on CHRYSALIS-2 data, amivantamab plus lazertinib combination therapy demonstrated activity in all types of advanced EGFR-mutant lung cancer. These include common EGFR mutations such as EGFR exon 20 insertion mutations and atypical EGFR-mutant lung cancer.

In addition to this [trial], there are several ongoing studies including the phase 2 PALOMA-2 study exploring the potential of subcutaneous amivantamab instead of [intravenous] amivantamab in combination with lazertinib in various different types of EGFR-mutant lung cancer.


  1. Cho BC, Wang Y, Felip E, et al. Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): results from CHRYSALIS-2. J Clin Oncol. 2024;42(suppl 16):8516.
  2. A study of amivantamab in participants with advanced or metastatic solid tumors including epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (PALOMA-2). Accessed May 31, 2024.
Recent Videos
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
The approval for epcoritamab in patients with R/R follicular lymphoma was supported by encouraging efficacy findings from the phase 1/2 EPCORE NHL-1 trial.
Related Content